Back to Search
Start Over
Temsirolimus-resistant, checkpoint-deficient, homeostatic cytokine-responsive autologous TH1/TC1 cells for therapy of relapsed, refractory multiple myeloma (RRMM).
- Source :
-
Cytotherapy (Elsevier Inc.) . 2021 Supplement, Vol. 23 Issue 5, pS86-S86. 1p. - Publication Year :
- 2021
- Subjects :
- *MULTIPLE myeloma
*CELLULAR therapy
Subjects
Details
- Language :
- English
- ISSN :
- 14653249
- Volume :
- 23
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Cytotherapy (Elsevier Inc.)
- Publication Type :
- Academic Journal
- Accession number :
- 150257532
- Full Text :
- https://doi.org/10.1016/S1465324921004011